Yes, Acana dog food faces a 2025 class action lawsuit in New York alleging that its grain-free formulas are linked to dilated cardiomyopathy (DCM), a serious heart disease that weakens the heart muscle. The lawsuit, filed by plaintiff Zabnicki, centers on a disturbing case: a dog that consumed multiple Acana grain-free varieties purchased from Chewy between 2023 and 2025 developed heart failure and died at just 2.5 years old. The claim alleges that Acana grain-free formulas lacked critical nutrients—iron, thiamine, calcium, riboflavin, folate, and niacin—that are essential for maintaining heart health, supporting metabolism, and protecting the nervous system.
The maker of Acana, Champion Petfoods (owned by Mars Petcare), allegedly marketed these grain-free products as “complete, health-forward nutrition” and “fully balanced, everyday nutrition” without disclosing potential cardiac risks or revealing the nutritional gaps that the plaintiff’s legal team claims exist. This case is not isolated. The FDA launched a formal investigation in July 2018 into potential links between grain-free diets high in legumes—such as peas and lentils—and increased DCM incidence in dogs, with Acana grain-free formulas explicitly named among the brands under scrutiny.
Table of Contents
- What Is Dilated Cardiomyopathy and Why Is It Linked to Grain-Free Dog Food?
- Nutritional Deficiencies Alleged in Acana Grain-Free Formulas
- The Original 2018 Class Action Against Champion Petfoods
- What the Marketing Claims Promised Versus What the Food Allegedly Delivered
- The FDA Investigation and Its Limitations in Protecting Dogs
- Which Dogs May Be at Higher Risk
- The Timeline of Acana Consumption and Symptom Development
What Is Dilated Cardiomyopathy and Why Is It Linked to Grain-Free Dog Food?
Dilated cardiomyopathy (DCM) is a condition where the heart muscle becomes enlarged and weakened, reducing its ability to pump blood efficiently. In the Zabnicki case, this disease proved fatal: the dog’s heart failure progressed rapidly after consuming Acana’s grain-free formulations. The FDA’s 2018 investigation was prompted by veterinarians and researchers reporting an uptick in DCM diagnoses among dogs eating grain-free diets high in legumes—ingredients that Acana grain-free formulas rely on heavily.
The hypothesis was that these diets might lack taurine or other amino acids, or that certain plant-based proteins could interfere with nutrient absorption. The FDA investigation ultimately concluded without establishing a definitive causal link between grain-free diets or legumes specifically and DCM in dogs. However, the absence of proof is not proof of absence. Many veterinarians remain concerned about grain-free feeding trends, and the Zabnicki lawsuit argues that even without FDA confirmation, Champion’s products contained documented nutritional deficiencies—particularly in iron, thiamine, calcium, riboflavin, folate, and niacin—that could contribute to cardiac dysfunction over time.
Nutritional Deficiencies Alleged in Acana Grain-Free Formulas
The Zabnicki class action specifically alleges that Acana grain-free formulas were deficient in six key nutrients, each with documented roles in cardiovascular and metabolic health. Iron is essential for oxygen transport in blood; thiamine (vitamin B1) supports energy metabolism; calcium is critical for muscle function, including heart muscle contraction; riboflavin (vitamin B2) aids in cellular energy production; folate plays a role in cellular division and metabolism; and niacin (vitamin B3) supports energy metabolism and nervous system function.
If a dog food lacks these nutrients, long-term consumption could theoretically weaken the heart’s ability to function optimally. This allegation is significant because Champion marketed its grain-free Acana products as “complete” and “fully balanced,” which, in pet food regulatory terms, implies that the diet meets all established nutrient requirements for adult dogs. If the plaintiff’s testing or analysis can demonstrate that these formulas fell below minimum standards for the nutrients listed, it could establish a material breach between the company’s marketing claims and the actual nutritional content of the food.
The Original 2018 Class Action Against Champion Petfoods
Before the Zabnicki cardiac lawsuit, another class action was filed in 2018 against Champion Petfoods, alleging that Orijen and Acana contained harmful levels of heavy metals and BPA (bisphenol A) while being falsely advertised as products with natural, quality ingredients. Champion denied these claims, arguing that any metal levels detected were negligible and remained well below regulatory limits set by the FDA and other agencies.
That earlier lawsuit, while distinct from the current cardiac claims, signaled longstanding concerns about the company’s product safety and truthfulness in marketing. The existence of multiple lawsuits against the same manufacturer raises a pattern-of-practice question: is this an isolated issue with certain production batches, or does it reflect broader quality control or transparency problems at the company? The Zabnicki case focuses on different alleged defects (nutrient deficiency and cardiac risk) than the 2018 suit (heavy metals and BPA), but both challenge Champion’s representations about product quality and safety.
What the Marketing Claims Promised Versus What the Food Allegedly Delivered
Champion marketed Acana grain-free formulas with language suggesting premium nutrition and complete health protection: “complete, health-forward nutrition” and “fully balanced, everyday nutrition.” These terms carry specific regulatory weight in the pet food industry. “Complete” means the food is formulated to provide all known essential nutrients in adequate amounts for the life stage stated on the label. “Fully balanced” suggests that the nutrient ratios are optimized and proportional.
If the Zabnicki lawsuit proves that Acana grain-free formulas lacked documented essential nutrients, then the marketing claims would be materially misleading to consumers who relied on them. Pet owners choosing grain-free products often do so because they believe they are purchasing a more carefully formulated, higher-quality option compared to conventional foods—a premium positioning that Champion reinforced through its marketing language. The tradeoff for consumers who bought based on these claims is that they may have paid a premium price for a product that, according to the lawsuit, did not deliver the nutritional completeness it promised.
The FDA Investigation and Its Limitations in Protecting Dogs
The FDA’s July 2018 investigation into grain-free diets and DCM was a significant regulatory action, acknowledging the agency’s concern that certain diet trends might pose health risks to dogs. Acana grain-free formulas were explicitly named in the FDA’s alert, placing the brand under direct scrutiny. However, the investigation’s conclusion—that no definitive causal link could be established—illustrates a major limitation in food safety regulation: proving causation in retrospective studies of companion animals is extremely difficult. Dogs that develop DCM may have genetic predispositions, may have consumed different foods at different life stages, and cannot provide detailed medical histories the way human patients can.
This regulatory gap is important to understand. The absence of FDA confirmation that grain-free diets cause DCM does not mean the foods are safe; it means the evidence was insufficient to prove the mechanism in a way that would satisfy regulatory standards. The Zabnicki lawsuit takes a different approach by focusing on demonstrable nutrient deficiencies rather than trying to prove the disease mechanism. This is a practical warning for dog owners: regulatory clearance and legal claims are separate questions, and the absence of an FDA ban does not guarantee that a product is risk-free, particularly for breeds or individual dogs with genetic vulnerability to heart disease.
Which Dogs May Be at Higher Risk
While the Zabnicki case involved a single dog that died young, DCM is not equally distributed across all dogs and diets. Certain breeds—including Golden Retrievers, Labradors, Cocker Spaniels, and Dalmatians—have higher baseline genetic predispositions to DCM. If a genetically susceptible dog is also fed a grain-free diet lacking in critical nutrients, the cumulative risk might increase substantially.
The plaintiff’s dog’s death at 2.5 years is notably young for DCM in large-breed dogs, which suggests either an unusually aggressive progression or an unusually significant nutritional insult. This distinction matters for pet owners evaluating their own dogs’ risk. A dog with a family history of heart disease, or a breed known to be vulnerable to DCM, may face higher stakes from nutritional deficiencies than a low-risk breed. The Zabnicki case demonstrates that even grain-free formulas purchased from a major retailer (Chewy) and consumed regularly over years can potentially contribute to serious, fatal outcomes.
The Timeline of Acana Consumption and Symptom Development
The Zabnicki lawsuit specifically notes that the dog consumed multiple Acana grain-free varieties between 2023 and 2025, a roughly two-year window before the heart failure that proved fatal at 2.5 years of age. This timeline is important because it establishes both regular, sustained exposure to the product and a relatively rapid development of a serious disease.
Two years of grain-free feeding followed by fatal DCM suggests either a severe nutritional deficiency working cumulatively over time or a particularly vulnerable dog whose genetic predisposition was triggered by dietary inadequacy. The specific window of purchase dates also anchors the case to a defined period of product formulation, allowing analysis of whether the nutrient composition of Acana grain-free formulas during 2023-2025 differed from what the company claimed in its marketing materials. If formulations changed over time or if there were batch-to-batch variations, this timeline narrows the legal inquiry to specific products and versions.
- —